S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?

Pharmaceutical Stocks List

Compare pharmaceutical stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$175.91
+1.6%
$147.52
$115.03
$376.65
$66.52B1.744.11 million shs3.64 million shs
AbbVie Inc. stock logo
ABBV
AbbVie
$161.18
+1.9%
$147.68
$115.10
$175.91
$285.04B0.696.61 million shs11.27 million shs
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$80.28
+1.6%
$74.37
$53.22
$81.17
$168.03B0.48.56 million shs18.39 million shs
GSK plc stock logo
GSK
GSK
$34.59
+0.7%
$31.71
$28.47
$46.97
$69.88B0.675.29 million shs4.09 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$178.00
+1.1%
$169.47
$155.72
$186.69
$460.38B0.575.90 million shs12.22 million shs
McKesson Co. stock logo
MCK
McKesson
$381.68
+0.1%
$366.29
$215.27
$401.78
$54.13B0.661.11 million shs1.79 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$110.12
+1.2%
$96.19
$71.50
$110.33
$275.95B0.388.49 million shs17.28 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$50.13
+1.3%
$45.78
$41.44
$61.71
$277.80B0.6917.65 million shs32.76 million shs
XPH
SPDR S&P Pharmaceuticals ETF
$42.92
+1.7%
$41.41
$37.94
$47.63
$218.89MN/A64,795 shs93,642 shs

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
+1.59%-0.51%+17.02%+26.60%-50.09%
AbbVie Inc. stock logo
ABBV
AbbVie
+1.88%+1.12%+10.10%+16.42%+39.82%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
+1.58%+1.44%+3.63%+16.20%+49.69%
GSK plc stock logo
GSK
GSK
+0.67%+2.67%+4.28%+9.15%-15.88%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+1.08%+0.56%+2.32%+7.66%+14.15%
McKesson Co. stock logo
MCK
McKesson
-0.03%+0.24%-1.97%+4.91%+76.08%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+1.18%+3.09%+8.81%+26.36%+47.00%
Pfizer Inc. stock logo
PFE
Pfizer
+1.29%+2.62%+7.69%+7.51%-6.70%
XPH
SPDR S&P Pharmaceuticals ETF
+1.71%+2.58%+1.42%+2.02%-6.27%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Moderna, Inc. stock logo
MRNA
Moderna
2.27 of 5 Stars
2.24.00.04.61.63.31.3
AbbVie Inc. stock logo
ABBV
AbbVie
2.62 of 5 Stars
2.25.04.23.92.41.71.3
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.77 of 5 Stars
2.24.04.24.02.72.51.9
GSK plc stock logo
GSK
GSK
2.39 of 5 Stars
0.05.03.30.02.30.01.9
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.57 of 5 Stars
2.23.04.23.91.82.51.9
McKesson Co. stock logo
MCK
McKesson
2.42 of 5 Stars
1.45.03.33.02.52.51.9
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.67 of 5 Stars
2.44.04.24.41.92.51.3
Pfizer Inc. stock logo
PFE
Pfizer
2.91 of 5 Stars
3.23.04.24.41.31.72.5
XPH
SPDR S&P Pharmaceuticals ETF
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Moderna, Inc. stock logo
MRNA
Moderna
2.42
Hold$176.930.58% Upside
AbbVie Inc. stock logo
ABBV
AbbVie
2.40
Hold$158.56-1.63% Downside
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.38
Hold$79.00-1.59% Downside
GSK plc stock logo
GSK
GSK
1.89
Hold$1,589.174,494.30% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.36
Hold$181.331.87% Upside
McKesson Co. stock logo
MCK
McKesson
2.80
Moderate Buy$395.913.73% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.82
Moderate Buy$106.00-3.74% Downside
Pfizer Inc. stock logo
PFE
Pfizer
2.36
Hold$56.4712.64% Upside
XPH
SPDR S&P Pharmaceuticals ETF
0.00
N/AN/AN/A

Current Analyst Ratings

Latest Pharmaceutical Stocks Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/30/2022
GSK plc stock logo
GSK
GSK
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetGBX 1,650 ➝ GBX 1,535
11/23/2022
Pfizer Inc. stock logo
PFE
Pfizer
Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$55.00
11/17/2022
AbbVie Inc. stock logo
ABBV
AbbVie
Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$170.00
11/17/2022
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$78.00
11/17/2022
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$170.00
11/17/2022
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$120.00
11/17/2022
Pfizer Inc. stock logo
PFE
Pfizer
Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$55.00
11/15/2022
Moderna, Inc. stock logo
MRNA
Moderna
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$160.00 ➝ $182.00
11/15/2022
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$105.00
11/14/2022
McKesson Co. stock logo
MCK
McKesson
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral$345.00 ➝ $376.00
11/11/2022
GSK plc stock logo
GSK
GSK
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Sell
(Data available from 12/1/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Moderna, Inc. stock logo
MRNA
Moderna
$18.47B3.66$30.92 per share5.69$46.83 per share3.76
AbbVie Inc. stock logo
ABBV
AbbVie
$56.20B5.07$17.97 per share8.97$9.06 per share17.79
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$46.39B3.68$12.58 per share6.38$15.40 per share5.21
GSK plc stock logo
GSK
GSK
$46.91B1.50$3.70 per share9.34$5.05 per share6.85
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$93.78B4.96$12.81 per share13.90$28.53 per share6.24
McKesson Co. stock logo
MCK
McKesson
$263.97B0.21$31.67 per share12.05($8.81) per share-43.32
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$48.70B5.73$7.43 per share14.82$17.56 per share6.27
Pfizer Inc. stock logo
PFE
Pfizer
$81.29B3.46$5.48 per share9.14$16.55 per share3.03
XPH
SPDR S&P Pharmaceuticals ETF
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Moderna, Inc. stock logo
MRNA
Moderna
$12.20B$27.646.3638.411.2555.00%70.03%45.09%2/23/2023 (Estimated)
AbbVie Inc. stock logo
ABBV
AbbVie
$11.54B$7.4921.5214.114.4623.19%155.88%16.96%2/1/2023 (Estimated)
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$6.99B$3.0726.1510.171.8714.29%50.30%16.29%2/3/2023 (Estimated)
GSK plc stock logo
GSK
GSK
$6.03B$8.164.2410.171.1837.88%32.18%7.69%2/8/2023 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$20.88B$7.1824.7917.333.5219.95%35.37%14.86%1/24/2023 (Estimated)
McKesson Co. stock logo
MCK
McKesson
$1.11B$14.1726.9414.491.530.76%-267.09%5.61%2/1/2023 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$13.05B$6.0118.3215.001.4425.88%46.57%18.24%2/2/2023 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$21.98B$5.209.6410.340.6229.81%43.95%19.80%2/14/2023 (Estimated)
XPH
SPDR S&P Pharmaceuticals ETF
N/AN/A0.00N/AN/AN/AN/AN/A

Latest Pharmaceutical Stocks Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/2/2022Q3 2022
GSK plc stock logo
GSK
GSK
$0.90$1.09+$0.19-$3.76$7.75 billion$9.22 billion
10/28/2022Q3 22
AbbVie Inc. stock logo
ABBV
AbbVie
$3.57$3.66+$0.09N/A$14.95 billion$14.81 billion      
10/27/2022Q3 2022
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$1.67$1.85+$0.18$2.42$14.05 billion$14.96 billion    
10/26/2022N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.83$1.99+$0.16N/A$11.18 billion$11.22 billion      
10/18/2022Q3 22
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.49$2.55+$0.06N/A$23.44 billion$23.79 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
AbbVie Inc. stock logo
ABBV
AbbVie
$5.643.50%+10.37%75.30%50 Years
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.162.69%+7.68%70.36%15 Years
GSK plc stock logo
GSK
GSK
$1.243.58%N/A15.20%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.522.54%+5.78%62.95%60 Years
McKesson Co. stock logo
MCK
McKesson
$2.160.57%+6.83%15.24%14 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.762.51%+9.88%45.92%11 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.603.19%+4.39%30.77%11 Years
XPH
SPDR S&P Pharmaceuticals ETF
$0.671.56%N/AN/AN/A

Latest Pharmaceutical Stocks Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/28/2022
AbbVie Inc. stock logo
ABBV
AbbVie
Quarterly$1.484.01%1/12/20231/13/20232/15/2023
11/2/2022
GSK plc stock logo
GSK
GSK
quarterly$0.36956.1%11/17/202211/18/20221/12/2023
11/30/2022
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.732.7%12/14/202212/15/20221/9/2023
10/26/2022
McKesson Co. stock logo
MCK
McKesson
quarterly$0.540.56%11/30/202212/1/20221/3/2023
10/19/2022
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Quarterly$1.132.74%11/21/202211/22/202212/6/2022
9/22/2022
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.403.64%11/3/202211/4/202212/5/2022
9/9/2022
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.413.98%10/13/202210/14/202211/15/2022
9/14/2022
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Quarterly$0.543.01%10/6/202210/7/202211/1/2022
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Moderna, Inc. stock logo
MRNA
Moderna
0.05
2.10
1.80
AbbVie Inc. stock logo
ABBV
AbbVie
3.77
0.93
0.83
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
1.13
1.42
1.31
GSK plc stock logo
GSK
GSK
2.22
0.97
0.74
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.37
1.43
1.18
McKesson Co. stock logo
MCK
McKesson
N/A
0.96
0.55
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.64
1.46
1.22
Pfizer Inc. stock logo
PFE
Pfizer
0.35
1.59
1.37
XPH
SPDR S&P Pharmaceuticals ETF
N/AN/AN/A

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Moderna, Inc. stock logo
MRNA
Moderna
2,700384.18 million317.72 millionOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
32,2002.13 billion2.12 billionOptionable
GSK plc stock logo
GSK
GSK
90,0962.03 billion1.83 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
141,7002.61 billion2.61 billionOptionable
McKesson Co. stock logo
MCK
McKesson
75,000141.79 million141.50 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
68,0002.54 billion2.53 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
79,0005.61 billion5.61 billionOptionable
XPH
SPDR S&P Pharmaceuticals ETF
N/A5.10 millionN/AOptionable

Pharmaceutical Stocks Headlines

SourceHeadline
XPH: U.S. Pharmaceuticals Stocks Are Probably Fairly Valued, Cyclically UnattractiveXPH: U.S. Pharmaceuticals Stocks Are Probably Fairly Valued, Cyclically Unattractive
seekingalpha.com - November 13 at 3:57 AM
Chevron, Uber Technologies, And A Way To Bet Against The Big Guys Are CNBCs Final TradesChevron, Uber Technologies, And A Way To 'Bet Against The Big Guys' Are CNBC's 'Final Trades'
msn.com - November 2 at 7:47 PM
Discerning Dealmaking: Caution Flag Still Raised in Biopharma M&A RaceDiscerning Dealmaking: Caution Flag Still Raised in Biopharma M&A Race
pharmexec.com - October 11 at 7:03 PM
MDYG SPDR S&P 400 Mid Cap Growth ETFMDYG SPDR S&P 400 Mid Cap Growth ETF
seekingalpha.com - October 1 at 6:13 AM
SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.1320SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.1320
seekingalpha.com - September 21 at 4:56 AM
Drug ETFs Likely Winners of Health LawDrug ETFs Likely Winners of Health Law
thestreet.com - September 7 at 7:04 PM
Obamacare Still Sickly, After All These YearsObamacare Still Sickly, After All These Years
thestreet.com - September 5 at 11:22 PM
When Spdr S&p Biotech (XBI) Moves Investors should ListenWhen Spdr S&p Biotech (XBI) Moves Investors should Listen
news.stocktradersdaily.com - August 24 at 7:51 AM
SPDR S&P Pharmaceuticals ETF NewsSPDR S&P Pharmaceuticals ETF News
thestreet.com - July 2 at 9:37 PM
Gordon Pape’s mailbag: Pharma ETFs, tax losses, undeclared capital gains and other investing questionsGordon Pape’s mailbag: Pharma ETFs, tax losses, undeclared capital gains and other investing questions
theglobeandmail.com - May 24 at 10:36 AM
In a Sick Market, Can Pharmas Help?In a Sick Market, Can Pharmas Help?
realmoney.thestreet.com - May 3 at 10:08 AM
12.8% of XPH Holdings Seeing Recent Insider Buys12.8% of XPH Holdings Seeing Recent Insider Buys
nasdaq.com - April 27 at 12:36 PM
Insiders Buy the Holdings of XPH ETFInsiders Buy the Holdings of XPH ETF
nasdaq.com - March 18 at 6:12 PM
Viatris stands out amid selloff in generic drugmakersViatris stands out amid selloff in generic drugmakers
seekingalpha.com - March 5 at 2:40 PM
Is SPDRSP PHARMA (XPH) a Strong ETF Right Now?Is SPDRSP PHARMA (XPH) a Strong ETF Right Now?
nasdaq.com - November 15 at 3:10 PM
Thursdays ETF with Unusual Volume: XPHThursday's ETF with Unusual Volume: XPH
nasdaq.com - November 4 at 4:25 PM
Will the Pfizer share price look healthy after earnings?Will the Pfizer share price look healthy after earnings?
cmcmarkets.com - July 28 at 10:36 AM
First Trust Takes New Buffered ETF AngleFirst Trust Takes New Buffered ETF Angle
etf.com - July 16 at 12:35 AM
The 2 Best Pharma Stocks to Buy on DipsThe 2 Best Pharma Stocks to Buy on Dips
stocknews.com - June 22 at 1:26 PM
SPDR S&P Pharmaceuticals ETFSPDR S&P Pharmaceuticals ETF
realmoney.thestreet.com - June 20 at 12:43 AM
U.S.-China Tensions Flare Up: Sector ETFs At RiskU.S.-China Tensions Flare Up: Sector ETFs At Risk
msn.com - April 9 at 2:03 PM
Billionaire Paul Tudor Jones’ Top 10 Stock Picks and Latest PortfolioBillionaire Paul Tudor Jones’ Top 10 Stock Picks and Latest Portfolio
finance.yahoo.com - March 25 at 3:22 PM
FDA Pushback on AbbVie Drug Raises More Alarms for BiotechnologyFDA Pushback on AbbVie Drug Raises More Alarms for Biotechnology
finance.yahoo.com - March 17 at 1:58 PM
FDA pushback on AbbVie drug raises more alarms for biotechFDA pushback on AbbVie drug raises more alarms for biotech
chicagobusiness.com - March 17 at 1:58 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Bristol-Myers Squibb logo

Bristol-Myers Squibb

NYSE:BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
GSK logo

GSK

NYSE:GSK
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
McKesson logo

McKesson

NYSE:MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Merck & Co., Inc. logo

Merck & Co., Inc.

NYSE:MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

SPDR S&P Pharmaceuticals ETF

NYSEARCA:XPH
SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.